Posts

Non-Small Cell Lung Cancer (NSCLC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Non-Small Cell Lung Cancer (NSCLC) Emerging Therapy and TPP Insights Thelansis’s “Non-Small Cell Lung Cancer (NSCLC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Non-Small Cell Lung Cancer (NSCLC) Overview Non-small cell lung cancer (NSCLC) is the predominant form of lung cancer, accounting for approximately 85% of all cases. Around 15–20% are diagnosed at an early stage, where surgical resection, often combined with adjuvant chemotherapy or radiotherapy, offers the best chance of cure. Risk factors can be divided into modifiable and non‑modifiable categories. Modifiable risks include tobacco smoking, secondhand smoke, and occupational or environmental exposures such as asbestos, radon, arsenic, chromium, nickel, ionizing radiation, ...
Post a Comment
Read more

Trigeminal Autonomic Cephalgias (TACs) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Trigeminal Autonomic Cephalgias (TACs) Emerging Therapy and TPP Insights Thelansis’s “Trigeminal Autonomic Cephalgias (TACs) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Trigeminal Autonomic Cephalgias (TACs) Overview Trigeminal autonomic cephalgias (TACs) are a distinct group of primary headache disorders characterised by strictly unilateral, severe trigeminal distribution pain invariably accompanied by ipsilateral cranial autonomic features — lacrimation, conjunctival injection, rhinorrhoea, ptosis, and eyelid oedema — reflecting activation of the trigeminovascular system and parasympathetic outflow via the sphenopalatine ganglion. The TAC spectrum encompasses cluster headache — the most prevalent and severe form — paroxysmal hemic...
Post a Comment
Read more

Persistent Corneal Epithelial Defect (PCED) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Persistent Corneal Epithelial Defect (PCED) Emerging Therapy and TPP Insights Thelansis’s “Persistent Corneal Epithelial Defect (PCED) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Persistent Corneal Epithelial Defect (PCED) Overview Persistent corneal epithelial defect (PCED) is a severe ocular pathology defined by the failure of the corneal epithelium to close within two weeks despite standard management. Resulting from a disrupted regenerative cycle, it stems from neurotrophic keratopathy, limbal stem cell deficiency, chemical burns, or severe ocular surface disease. Left untreated, chronic defects risk stromal melting, perforation, and permanent scarring. Diagnosis relies on slit-lamp biomicroscopy with fluorescein staining, corne...
Post a Comment
Read more

Herpetic Keratitis (HK) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Herpetic Keratitis (HK) Emerging Therapy and TPP Insights Thelansis’s “Herpetic Keratitis (HK) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Herpetic Keratitis (HK) Overview Herpetic keratitis (HK) is a leading infectious cause of corneal blindness worldwide, caused predominantly by herpes simplex virus type 1 (HSV-1) — and less commonly HSV-2 — following primary ocular infection and subsequent latency establishment within the trigeminal ganglion, with recurrent reactivation driving progressive corneal damage. The pathophysiology involves both direct viral cytopathic injury to corneal epithelium and immune-mediated stromal inflammation, producing distinct clinical entities: epithelial keratitis — characterised by pathognomonic dendrit...
Post a Comment
Read more

Uveitis Disease – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Uveitis Disease Emerging Therapy and TPP Insights Thelansis’s “Uveitis Disease Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Uveitis Disease Overview Uveitis is a heterogeneous group of intraocular inflammatory disorders affecting the uveal tract — iris, ciliary body, and choroid — classified anatomically as anterior, intermediate, posterior, or panuveitis, with anterior uveitis representing the most prevalent form. The pathophysiology encompasses both infectious triggers — including herpesviruses, toxoplasma, tuberculosis, and syphilis — and non-infectious immune-mediated mechanisms, the latter frequently associated with systemic conditions including HLA-B27-associated spondyloarthropathies, sarcoidosis, Behçet disease...
Post a Comment
Read more

Global Congenital Adrenal Hyperplasia (CAH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035

Global Congenital Adrenal Hyperplasia (CAH) Market Outlook Thelansis’s “Global Congenital Adrenal Hyperplasia (CAH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Adrenal Hyperplasia (CAH) treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America). Global Congenital Adrenal Hyperplasia (CAH) Overview Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive adrenal steroidogenesis disorders, with 21-hydroxylase deficiency caused by CYP21A2 mutations accounting for over 90% of cases, disrupting cortisol and aldosterone biosynthesis while redirecting steroid...
Post a Comment
Read more

Global Angelman Syndrome (AS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035

Global Angelman Syndrome (AS) Market Outlook Thelansis’s “Global Angelman Syndrome (AS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Angelman Syndrome (AS) treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America). Global Angelman Syndrome (AS) Overview Angelman Syndrome is a neurogenetic disorder caused by loss of maternal UBE3A expression, impairing ubiquitin-mediated protein degradation and synaptic function. It presents with severe intellectual disability, absent speech, ataxic gait, seizures, and a characteristically happy demeanor. Diagnosis combines methylation analysis...
Post a Comment
Read more